Protein expression of p53, bcl-2, and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer

Surgery

Volumn 120, Issue 2, 1996, Pages 159-167

  Moul, J W ^a   Bettencourt, M C ^a   Sesterhenn, I A ^a   Mostofi, F K ^a   McLeod, D G ^a   Srivastava, S ^a   Bauer, J J ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; PROTEIN P53;

ARTICLE; CANCER RECURRENCE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

EID: 0029819406     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(96)80283-2     Document Type: Article

References (28)

1. Boring CC Squires TS Tong T Cancer statistics 1994 CA Cancer J Clin 44 1994 7 26
2. Lu-Yao GL McLerran D Wasson J Wennberg JE An assessment of radical prostatectomy: time trends, geographic variation and outcomes JAMA 269 1993 2633 2636
3. Partin AW Piantodosi S Sanda MG Selection of men at high risk for disease recrrence for experimental adjuvant therapy following radical prostatectomy Urology 45 1995 831 838
4. [review] Shanky TV Kallioniema OP Koslowskim HM Consensus review of the clinical utility of DNA content cytometry in prostate cancer Cytometry 14 1993 497 500
5. Veltri RW Partin AW Epstein JE Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression J Cell Biochem Suppl 19 1994 249 258
6. Moul JW Friedrichs PA Lance RS Theune SM Chang EH Infrequent ras oncogene mutations in human prostate cancer Prostate 20 1992 327
7. [review] Kuhn EJ Kurnot RA Sesterhenn IA Chang EH Moul JW Expression of the c erb B2 (HER-2/neu) oncoprotein in human prostatic carcinoma J Urol 150 1993 1427 1433
8. Umbas R Isaacs WB Brinquier PP Decreased E-Cadherin expression is associated with poor prognosis in patients with prostate cancer Cancer Res 54 1994 3929 3933
9. Moul JW MayGarden SJ Ware JL Cathpsin-D and epidermal growth factor receptor EGFR: immunohistochemistry does not predict recurrence of prostate cancer patients undergoing radical prostatectomy J Urol 155 1996 982 985
10. Thomas DJ Robinson M King P p53 expression and clinical outcome in prostate cancer Br J Urol 72 1993 778 781
11. Shurbaji MS Kalbfleisch JH Thurmond TS Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer Hum Pathol 26 1995 106 109
12. Bauer JJ Sesterhenn IA Mostofi FK McLeod DG Srivastava S Moul JW p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy Clin Cacxer Res 1 1995 1295 1300
13. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol (in press).
14. Brown DC Gatter KC Monoclonal antibody Ki-67: its use in histopathology Histopathology 17 1990 489 503
15. Noordzij M van der Kwast T van Steenbrugge G van Weerden W Oomen M Schroder F Determination of Ki-67 defined growth fraction by monoclonal antibody MIB1 in formalin-fixed, paraffin-embedded prostatic cancer tissues Prostate 27 1995 154 159
16. Partin AW Oesterling JE The clinical usefulness of PSA: update J Urol 152 1994 1358 1363
17. Gleason DF Histological grading and clinical staging of prostate carcinoma Tannenbaum M Urologic pathology: the prostate 1977 Lea & Fedinger Philadelphia 171 197
18. Mostofi DF Sesterhenn IA Sobin LH Histological typing of prostate tumors 1990 World Health Organization Geneva
19. Obovi M Wheeler TM Scardino PT The American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer Cancer 73 1994 104 114
20. Kaplan EL Meier P Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
21. Cox DR Regression models and life-tables (with discussion) J R Stat Soc Ser B 34 1972 187 202
22. Bookstein R MacGrogan D Hilsenbeck SG Sharkey F Allred DC p53 is mutated in a subset of advanced-stage prostate cancer Cancer Res 53 1993 3369 3373
23. Navone NM Troncoso P Pisters LL p53 protein accumulation and gene mutation in the progression of human prostate carcinoma J Natl Cancer Inst 85 1993 1657 1669
24. McDonnell TJ Tumcoso P Brisbay SM Expression of the proto-oncogenes bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940 6944
25. Piris MA Pezzela F Martinez-Montero JC p53 and bcl-2 expression in high grade B-cell lymphomas:correlation with survival time Br J Cancer 69 1994 337
26. Silverstrini R Verneroni S Daidone MG The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients J Natl Cancer Inst 16 1994 449 504
27. Marin MC Hsu B Meyn RE Donehower LA El-Naggar AK McDonnell TJ Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis Oncogene 9 1994 3107
28. Berges RR Furuya Y Remington L English HF Jacks T Isaacs JT Cell proliferation, DNA repair, and p53 function are not required for programmed cell death of prostatic glandular cells induced by androgen ablation Proc Natl Acad Sci 90 1993 8910